Previous close | 20.40 |
Open | N/A |
Bid | 15.00 |
Ask | 19.80 |
Strike | 550.00 |
Expiry date | 2025-12-19 |
Day's range | 20.40 - 20.40 |
Contract range | N/A |
Volume | |
Open interest | 1 |
Regeneron Pharmaceuticals earnings and sales missed first-quarter estimates early Thursday. Shares fell slightly.
First quarter 2024 revenues decreased 1% to $3.15 billion versus first quarter 2023; excluding RonapreveTM(a)(b), revenues increased 7%First quarter 2024 Dupixent® global net sales (recorded by Sanofi) increased 24% to $3.08 billion versus first quarter 2023First quarter 2024 U.S. net sales for EYLEA® HD and EYLEA® were $1.40 billion, including $200 million from EYLEA HDFirst quarter 2024 Libtayo® global net sales increased 45% to $264 million versus first quarter 2023First quarter 2024 GAAP dil
Let's look at five large-cap pharma/biotech companies slated to release quarterly results this week.